Volume | 957,552 |
|
|||||
News | - | ||||||
Day High | 0.9575 | Low High |
|||||
Day Low | 0.8513 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Eyenovia Inc | EYEN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.9248 | 0.8513 | 0.9575 | 0.9374 | 0.915 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
2,707 | 957,552 | US$ 0.9033261 | US$ 864,982 | - | 0.501 - 5.85 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:02:11 | formt | 100 | US$ 0.9369 | USD |
Eyenovia Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
41.03M | 44.12M | - | 4k | -27.26M | -0.62 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Eyenovia News
Date | Time | Source | News Article |
---|---|---|---|
3/18/2024 | 06:12 | IH Market News | Anticipation Builds on Wall Street for Federal Reserve’s.. |
3/11/2024 | 07:11 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
2/14/2024 | 15:13 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
2/14/2024 | 15:10 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
1/31/2024 | 07:13 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] |
1/25/2024 | 06:59 | Edgar (US Regulatory) | Form 8-K - Current report |
1/16/2024 | 07:24 | Edgar (US Regulatory) | Form 8-K - Current report |
12/05/2023 | 15:54 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
11/13/2023 | 15:53 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
11/13/2023 | 15:15 | Edgar (US Regulatory) | Form 8-K - Current report |
9/21/2023 | 07:00 | GlobeNewswire Inc. | Eyenovia to Participate in Panel Discussion at Cantor Global.. |
9/20/2023 | 07:23 | Edgar (US Regulatory) | Form 8-K - Current report |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EYEN Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.5475 | 0.9575 | 0.5412 | 0.7410771 | 1,843,482 | 0.3894 | 71.12% |
1 Month | 0.90 | 0.9578 | 0.501 | 0.6471046 | 1,605,340 | 0.0369 | 4.10% |
3 Months | 1.79 | 2.57 | 0.501 | 1.22 | 1,371,050 | -0.8531 | -47.66% |
6 Months | 1.49 | 2.57 | 0.501 | 1.33 | 855,955 | -0.5531 | -37.12% |
1 Year | 5.37 | 5.85 | 0.501 | 1.74 | 613,215 | -4.43 | -82.55% |
3 Years | 5.085 | 6.63 | 0.501 | 2.43 | 351,921 | -4.15 | -81.58% |
5 Years | 6.00 | 7.72 | 0.501 | 3.14 | 310,181 | -5.06 | -84.39% |
Eyenovia Description
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations. |